Showing articles associated with Emma Bolam

Emma Bolam is Head of Production at the Jenner Institute’s Clinical BioManufacturing Facility (CBF). She has been a researcher at Oxford for nearly 25 years and has helped to produce many vaccines now in clinical use.

What is you main area of interest/expertise?

I started as a research technician at the Therapeutic Antibody Centre where I was involved in the development and production of monoclonal antibodies, including CAMPATH-1H, now a licensed drug used to treat multiple sclerosis and chronic lymphocytic leukaemia.

Since the CBF was established in 2005, I have developed and produced the many CBF vaccines now used in clinical trials. 

What are you working on right now?

In April 2020, my production team and I manufactured the UK’s first COVID-19 vaccine (ChAdOx1 nCoV-19). We are soon to resume manufacture of a novel vaccine for Ebola virus disease.

Why is Oxford a good place to work in this field of research?

Oxford is at the forefront of vaccinology. As the CBF holds a Manufacturer’s Authorisation from the Medicines and Healthcare Products Regulatory Agency (MHRA), allowing us to manufacture vaccines for clinical use, we are able to provide a unique link between the Jenner Institute’s academic research and rapid clinical drug development

Emma Bolam